(Total Views: 941)
Posted On: 07/20/2020 2:53:15 PM
Post# of 154120
Agree the dosing schedule will not be controlled by a patent.
I am kind of struggling to find the right words to describe the extent to which Patterson's patent may intrude into leronlimab treatment protocol.
I suspect that Patterson's patent will not intrude for a variety of reasons. Patterson and CYDY are joined at the hip upon leron success for covid so they will want to maintain a good relationship. Patterson's lab cannot do one tenth of one percent of the RANTEs testing which will be needed in the case of leron success in covid. No doubt both CYDY and Patterson are well aware of this obvious fact.
Nevertheless, I still think that Patterson's patent filing is a source of friction between Patterson and CYDY but not likely to be a big deal, I think.
I am kind of struggling to find the right words to describe the extent to which Patterson's patent may intrude into leronlimab treatment protocol.
I suspect that Patterson's patent will not intrude for a variety of reasons. Patterson and CYDY are joined at the hip upon leron success for covid so they will want to maintain a good relationship. Patterson's lab cannot do one tenth of one percent of the RANTEs testing which will be needed in the case of leron success in covid. No doubt both CYDY and Patterson are well aware of this obvious fact.
Nevertheless, I still think that Patterson's patent filing is a source of friction between Patterson and CYDY but not likely to be a big deal, I think.
(1)
(0)
